These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Soluble PD-1 can augment anti-tumor immunity induced by HSP70-peptide complex in tumor-bearing mice].
    Author: Wang XH, Zhang GM, He YF, Zhang H, Feng ZH.
    Journal: Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):655-8. PubMed ID: 15555427.
    Abstract:
    AIM: To explore the effect of soluble PD-1 (sPD-1) on the anti-tumor immunity induced by HSP70-peptide. METHODS: BALB/c mice were immunized with HSP70-peptide, then the cytotoxic activity of splenocytes was detected by MTT colorimetry. Expression of PD-1 and its ligand on splenocytes was determined by semi-quantitative RT-PCR. For some mice, sPD-1 plasmid was injected alone or in combination with HSP70-peptide and then the tumor weight and cytotoxic activity of splenocytes were measured. RESULTS: sPD-1 alone had anti-tumor effect. HSP70-peptide complex not only induced tumor-specific cytotoxic T lymphocytes(CTLs), but also promoted expression of PD-1 and its ligand. The combination of sPD-1 with HSP70-peptide complex induced much more stronger anti-tumor effect as compared with sPD-1 or HSP70-peptide alone. sPD-1 transfection in mice could enhance the cytotoxic activity of splenocytes from immunized mice. CONCLUSION: sPD-1 enhanced the anti-tumor efficacy of HSP70-peptide.
    [Abstract] [Full Text] [Related] [New Search]